Immunomedics, Inc. (NASDAQ:IMMU) Director Cynthia L. Goldenberg sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $10.72, for a total transaction of $428,800.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Cynthia L. Goldenberg also recently made the following trade(s):

  • On Wednesday, August 23rd, Cynthia L. Goldenberg sold 40,000 shares of Immunomedics stock. The shares were sold at an average price of $9.24, for a total transaction of $369,600.00.

Shares of Immunomedics, Inc. (NASDAQ IMMU) traded up 14.07% on Monday, hitting $11.84. 6,627,060 shares of the stock traded hands. Immunomedics, Inc. has a 52 week low of $2.02 and a 52 week high of $11.91. The firm’s market capitalization is $1.32 billion. The firm’s 50 day moving average is $8.65 and its 200 day moving average is $7.10.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.13. The firm had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $0.75 million. During the same period in the previous year, the company posted ($0.17) earnings per share. Immunomedics’s revenue was down 31.2% on a year-over-year basis. On average, analysts expect that Immunomedics, Inc. will post ($0.55) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Immunomedics, Inc. (IMMU) Director Sells $428,800.00 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/28/immunomedics-inc-immu-director-sells-428800-00-in-stock.html.

Large investors have recently made changes to their positions in the company. Teachers Advisors LLC raised its stake in shares of Immunomedics by 2.1% in the first quarter. Teachers Advisors LLC now owns 189,537 shares of the biopharmaceutical company’s stock valued at $1,226,000 after buying an additional 3,876 shares during the period. FMR LLC raised its stake in shares of Immunomedics by 34.6% in the first quarter. FMR LLC now owns 1,524,463 shares of the biopharmaceutical company’s stock valued at $9,863,000 after buying an additional 391,815 shares during the period. American International Group Inc. raised its stake in shares of Immunomedics by 17.8% in the first quarter. American International Group Inc. now owns 59,094 shares of the biopharmaceutical company’s stock valued at $382,000 after buying an additional 8,910 shares during the period. EAM Investors LLC purchased a new stake in shares of Immunomedics during the first quarter valued at $887,000. Finally, Atlantic Trust Group LLC purchased a new stake in shares of Immunomedics during the first quarter valued at $599,000. 77.99% of the stock is owned by institutional investors.

Several research analysts have weighed in on the stock. Wells Fargo & Company upgraded shares of Immunomedics from a “market perform” rating to an “outperform” rating in a research note on Friday, May 5th. Jefferies Group LLC set a $9.00 price objective on shares of Immunomedics and gave the company a “buy” rating in a research note on Saturday, May 6th. Cowen and Company assumed coverage on shares of Immunomedics in a research note on Friday, May 26th. They issued an “outperform” rating on the stock. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research upgraded shares of Immunomedics from a “sell” rating to a “buy” rating and set a $9.50 price objective on the stock in a research note on Tuesday, July 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and an average target price of $12.00.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.